Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10982543 | 1.00 | CDA (0.46) | CDAKDM4EGAAPOLBOPRM1 | |
| SCHEMBL6082054 | 1.00 | CDA (0.46) | CDAKDM4EGAAPOLBOPRM1 | |
| SCHEMBL11215508 | 0.94 | CDA (0.44) | CDAKDM4EGAAPOLBOPRM1 | |
| SCHEMBL19271812 | 0.92 | CDA (0.42) | CDAKDM4EOPRM1OPRL1ALDH1A1 | |
| SCHEMBL5951577 | 0.90 | CDA (0.38) | CDAOPRM1OPRL1ADORA3ADORA2A | |
| SCHEMBL3093245 | 0.88 | PDE7A (0.41) | KDM4EGAAPOLBOPRM1OPRL1 | |
| SCHEMBL17138754 | 0.88 | CDA (0.42) | CDAKDM4EGAAALDH1A1NOS3 | |
| SCHEMBL5866375 | 0.86 | CDA (0.46) | CDAKDM4EGAAPOLBNOS3 | |
| SCHEMBL5827421 | 0.85 | CDA (0.44) | CDAKDM4EALDH1A1NOS3NOS1 | |
| SCHEMBL9202125 | 0.85 | KDM4E (0.39) | KDM4EGAAPOLBOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3833665-B1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | ANTABIO SAS (FR) | 2023-07-19 | — | — | EP | claimed |
| US-11905286-B2 | Diazabicyclooctanones as inhibitors of serine beta-lactamases | ANTABIO SAS (FR) | 2024-02-20 | — | — | US | disclosed |
| CN-117384155-A | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-117384155-A | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2024007883-A1 | CLASS OF THIAZOLAMINE-DIAZABICYCLOOCTANONE CONJUGATED DERIVATIVES AND USE THEREOF | 福安药业集团重庆三禾兴医药科技有限公司 | 2024-01-11 | — | — | WO | disclosed |
| CN-111954671-B | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-111954671-B | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116144728-A | Culture medium of klebsiella pneumoniae resistant to ceftazidime avermectin | 湖北民族大学附属民大医院 | 2023-05-23 | — | — | CN | disclosed |
| CN-111072660-B | Simple preparation method of rilibatan | 新发药业有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-111954671-A | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2020-11-17 | — | — | CN | disclosed |
| CN-111954671-A | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2020-11-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905286-B2 | Diazabicyclooctanones as inhibitors of serine beta-lactamases | STS, BCKDK, PEPD | CDA 1518/4885KDM4E 1255/4885GAA 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.